Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 18/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8290900 | 0.84 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3CYP2D6CYP3A4 | |
| SCHEMBL7085751 | 0.82 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7751548 | 0.81 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3CYP2D6CYP3A4 | |
| SCHEMBL3466139 | 0.79 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL3466142 | 0.79 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL7947168 | 0.79 | SLC6A2 (0.48) | SLC6A4SLC6A2SLC6A3CYP2D6CYP3A4 | |
| SCHEMBL7077339 | 0.78 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3CYP2D6CYP3A4 | |
| SCHEMBL6139409 | 0.77 | SLC6A4 (0.85) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL3466791 | 0.77 | SLC6A4 (0.85) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL6543325 | 0.76 | SLC6A4 (0.83) | SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073838-A1 | 3-alkyl-3-phenyl-piperidines | CHEN MICHAEL HUAI GU (US) | 2003-04-17 | — | — | US | claimed |
| US-20010037023-A1 | 3-alkyl-3-phenyl-piperidines | CHEN MICHAEL HUAI GU (US) | 2001-11-01 | — | — | US | claimed |
| WO-1998011090-A2 | 3-ALKYL-3-PHENYL-PIPERIDINES | WARNER-LAMBERT COMPANY (US) | 1998-03-19 | — | — | WO | claimed |
| US-6602886-B2 | 3-alkyl-3-phenyl-piperidines | WARNER-LAMBERT COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-20030073838-A1 | 3-alkyl-3-phenyl-piperidines | CHEN MICHAEL HUAI GU (US) | 2003-04-17 | — | — | US | disclosed |
| US-6433178-B2 | ALKYL PYRIMIDINES SUBSTITUTED PIPERIDINE DERIVATIVES ARE USED AS TACHYKININ ANTAGONSIT, USEFUL IN THE TREATMENT OF PAIN, DEPRESSION, ANXIETY, PANIC, SCHIZOPHRENIA, NEURALGIA, ADDICTION DISORDER, INFLAMMATION, AND NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2002-08-13 | — | — | US | disclosed |
| US-20010037023-A1 | 3-alkyl-3-phenyl-piperidines | CHEN MICHAEL HUAI GU (US) | 2001-11-01 | — | — | US | disclosed |
| US-6040316-A | TACHYKININ ANTAGONISTS TREATING PAIN, DEPRESSION, ANXIETY, PANIC, SCHIZOPHRENIA, NEURALGIA, ADDICTION DISORDERS, INFLAMMATORY DISEASES, GASTROINTESTINAL DISORDERS, VASCULAR DISORDERS, AND NEUROPATHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037023-A1 | 3-alkyl-3-phenyl-piperidines | TAC3, KCNK3, ACKR3 | SLC6A4 89/4885SLC6A2 269/4885SLC6A3 16/4885 |
| US-20030073838-A1 | 3-alkyl-3-phenyl-piperidines | TAC3, KCNK3, ACKR3 | SLC6A4 89/4885SLC6A2 269/4885SLC6A3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.